On October 31, the U.S. District Court for the Eastern District of Virginia granted a preliminary injunction blocking the U.S. Patent Office’s Claims and Continuations Rules from taking effect. While the rules are on hold, nutraceutical companies need to remain informed so they can make decisions that will maximize the value of their patent portfolios during these uncertain times. In her byline on www.nutraingredients-usa.com, Foley’s Courtenay Brinckerhoff highlights some of the arguments by Smithkline Beecham Corporation (GSK), who challenged the court on the rules, as well as the court’s decisions and the possible impact on nutraceutical companies
Click here for the full article.
Author(s)
Related Insights
20 December 2024
Health Care Law Today
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked and replaced FDA’s October 2, 2024, decision on tirzepatide.
20 December 2024
Manufacturing Industry Advisor
Christmas Came Early: Justice Delivered in Supplier Dispute Over Unjust Enrichment
The AirBoss saga continues… This holiday season, AirBoss Flexible Products Co. received a monumental legal victory, righting a costly wrong in MSSC, Inc. v. AirBoss.
19 December 2024
Health Care Law Today
HIPAA Reproductive Health Care Amendments: Compliance in an Uncertain Enforcement Landscape
The amendments to the HIPAA Privacy Rule designed to protect reproductive health care information are under legal challenge as the compliance date quickly approaches.